跳至主要内容
临床试验/NCT03033641
NCT03033641已完成不适用

Feasibility of the CARTOFINDER™ 4D LAT Algorithm to Identify Ablation Target in Subjects With Atrial Fibrillation (FIND CAN Trial: "CF-172")

Biosense Webster, Inc.0 个研究点目标入组 25 人开始时间: 2016年12月5日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
25
主要终点
Evaluate mapping characteristics

研究概览

简要总结

The purpose of this feasibility study is to further explore characteristics of ablation targets identified by CARTOFINDER 4D LAT Algorithm in subjects with persistent atrial fibrillation and to assess the acute outcome of CARTOFINDER Guided Ablation in terms of the termination of atrial fibrillation to either Normal Sinus Rhythm or Atrial Tachycardia.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must meet the following inclusion criteria:
  • Age > 18 years.
  • Patients who have signed the Patient Informed Consent Form (ICF)
  • Scheduled to undergo a clinically-indicated catheter ablation procedure for treatment of persistent atrial fibrillation (defined as continuous atrial fibrillation that is sustained beyond seven consecutive days).
  • Drug-refractory atrial fibrillation. (failed 1 or more class I or III antiarrhythmic drugs) and demonstrating Persistent AF (requiring drugs or electrical shock to terminate)
  • Able and willing to comply with all pre-, post-, and follow-up testing and requirements (e.g. patients not confined by a court ruling)

排除标准

  • Subject who meet any of the following exclusion criteria are not eligible for enrollment.
  • Paroxysmal Atrial Fibrillation
  • Continuous AF > 12 months (1 Year) (Longstanding Persistent AF) 2.
  • Subjects previously diagnosed as Long Standing Persistent (LSP) but have demonstrated the ability to maintain Normal Sinus Rhythm for >30 days after cardioversion and have not been in AF greater than 1 year at the time of the procedure remain eligible for inclusion.
  • Previous ablation procedure for AF (previous ablation for the treatment of Flutter is acceptable)
  • Patients with a left atrial size >55 mm (echocardiography, parasternal long axis view).
  • Inability to restore sinus rhythm for 30 seconds or longer in the opinion of the investigator.
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
  • Atrial arrhythmia patients with structural atrial disease such as a prior history of atriotomy from prior atrial surgery, presence of an atrial septal defect, and/or presence of an atrial septal closure patch.
  • History of or current blood clotting or bleeding abnormalities, contraindication to systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin inhibitor), significant pulmonary disease, unstable angina, uncontrolled heart failure, acute illness or systemic infection, or any other disease or malfunction that would preclude treatment in the opinion of the investigator.
  • Enrollment in a study evaluating another device or drug.
  • A complex arrhythmia secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  • Patients with a prosthetic mitral valve or any mechanical valve
  • Any cardiac surgery within the past 60 days (2 months) (includes PCI) (bypass within the past year)
  • Subjects that have ever undergone valvular cardiac surgical procedure (ie, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)
  • Prior ICD or pacemaker implanted
  • Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.
  • Presence of a condition that precludes vascular access.
  • Subject has a contra-indication to any of the devices used in the study per the IFU
  • Women of child bearing potential who are pregnant, lactating, or planning to become pregnant during the course of the trial.

研究组 & 干预措施

Ablation procedure

Experimental

干预措施: Ablation procedure (Device)

结局指标

主要结局

Evaluate mapping characteristics

时间窗: Intraoperative

Explore characteristics of ablation targets identified by the CARTOFINDER 4D LAT Algorithm

Evaluate acute safety of freedom from procedure-related primary adverse events

时间窗: Within 7 days

Evaluate acute safety of freedom from procedure-related primary adverse events occurring within 7 days of ablation procedure

次要结局

  • Evaluate atrial fibrillation (AF) termination(Perioperative)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验